Study of Ataluren (PTC124) in Cystic Fibrosis

Last updated: March 11, 2020
Sponsor: PTC Therapeutics
Overall Status: Terminated

Phase

3

Condition

Lung Disease

Cystic Fibrosis

Scar Tissue

Treatment

N/A

Clinical Study ID

NCT02107859
PTC124-GD-023-CF
2013-005449-35
  • Ages > 6
  • All Genders

Study Summary

The primary objective of this study is to determine the long-term safety and tolerability of ataluren in participants with nonsense mutation cystic fibrosis (nmCF) who completed participation in the double-blind study PTC124-GD-009-CF (NCT00803205), as assessed by adverse events and laboratory abnormalities. The secondary objective of this study includes the assessment of the efficacy of ataluren, as measured by forced expiratory volume in 1 second (FEV1) and pulmonary exacerbation rate, and other safety parameters (for example, 12-lead electrocardiogram [ECG] measurements, vital signs).

Eligibility Criteria

Inclusion

Key Inclusion Criteria:

  • Ability to provide written informed consent (parental/guardian consent and participantassent if less than [<] 18 years of age).

  • Evidence of completed participation in the double-blind study, PTC124-GD-009-CF (Study 009).

  • Body weight greater than or equal to (≥) 16 kilograms (kg).

  • Performance of a valid, reproducible spirometry test using the study-specificspirometer during the screening period.

  • Confirmed laboratory values within the central laboratory ranges at screening.

  • In male and female participants who are sexually active, willingness to abstain fromsexual intercourse or employ a barrier or medical method of contraception during thestudy drug administration and 60-day follow-up period.

  • Willingness and ability to comply with all study procedures and assessments, includingscheduled visits, drug administration plan, laboratory tests, and study restrictions.

Exclusion

Key Exclusion Criteria:

  • Chronic use of systemic tobramycin within 4 weeks prior to screening.

  • Evidence of pulmonary exacerbation or acute upper or lower respiratory tract infection (including viral illnesses) within 3 weeks prior to screening or between screening andrandomization.

  • Any change (initiation, change in type of drug, dose modification, schedulemodification, interruption, discontinuation, or re-initiation) in a chronictreatment/prophylaxis regimen for CF or for CF-related conditions within 4 weeks priorto screening and randomization.

  • Known hypersensitivity to any of the ingredients or excipients of the study drug.

  • Exposure to another investigational drug within 4 weeks prior to screening.

  • Treatment with intravenous antibiotics within 3 weeks prior to screening.

  • History of solid organ or hematological transplantation.

  • Ongoing immunosuppressive therapy (other than corticosteroids).

  • Positive hepatitis B surface antigen, hepatitis C antibody test or humanimmunodeficiency virus (HIV) test.

  • Known portal hypertension.

  • Pregnancy or breast-feeding.

Study Design

Total Participants: 61
Study Start date:
May 23, 2014
Estimated Completion Date:
June 05, 2017

Connect with a study center

  • Hôpital Universitaire des Enfants Reine Fabiola

    Brussels,
    Belgium

    Site Not Available

  • University Hospital Brussels

    Brussels,
    Belgium

    Site Not Available

  • University Hospital Leuven

    Leuven,
    Belgium

    Site Not Available

  • Hôpital Necker - Enfants Malades

    Paris,
    France

    Site Not Available

  • Hôpital des Enfants

    Toulouse, 31059
    France

    Site Not Available

  • Klinikum der Universität Köln

    Köln,
    Germany

    Site Not Available

  • Hadassah University Hospital - Mount Scopus

    Jerusalem, 91240
    Israel

    Site Not Available

  • Università La Sapienza

    Roma,
    Italy

    Site Not Available

  • Azienda Ospedaliera di Verona

    Verona,
    Italy

    Site Not Available

  • Hospital Universitario La Paz

    Madrid,
    Spain

    Site Not Available

  • Karolinska University Hospital, Huddinge

    Stockholm,
    Sweden

    Site Not Available

  • University of Alabama-Birmingham

    Birmingham, Alabama 35233
    United States

    Site Not Available

  • Miller Children's Hospital Long Beach

    Long Beach, California 90806
    United States

    Site Not Available

  • Denver Children's Hospital

    Aurora, Colorado 80045
    United States

    Site Not Available

  • Children's Hospital Chicago

    Chicago, Illinois 60614
    United States

    Site Not Available

  • Children's Hospital Boston

    Boston, Massachusetts 02115
    United States

    Site Not Available

  • Beth Israel Medical Center

    New York, New York 10003
    United States

    Site Not Available

  • Beth Israel Medical Center

    New York City, New York 10003
    United States

    Site Not Available

  • Rainbow Babies & Children's Hospital

    Cleveland, Ohio 44106
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.